-- In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression or death by 81 percent when compared to a standard of care chemoimmunotherapy regimen, bendamustine plus rituximab (1)
-- Patients receiving VENCLEXTA plus rituximab achieved a high overall response rate (ORR) of 92 percent (1)
-- With this approval, VENCLEXTA plus rituximab is the first oral-based, chemotherapy-free combination with a fixed treatment duration for CLL
PR Newswire
NORTH CHICAGO, Ill., June 8, 2018